New Delhi, Dec. 10 -- The Delhi High Court on Wednesday restrained Sun Pharmaceutical Industries Ltd from selling or launching its generic version of semaglutide in India until the expiry of Danish innovator Novo Nordisk's patent in March 2026.

The court, however, permitted Sun Pharma to manufacture and export semaglutide to non-patent countries, extending to Sun the same relief it granted Dr. Reddy's Laboratories in a similar dispute earlier this month.

A bench of Justice Manmeet Pritam Singh Arora directed Sun Pharma to file an undertaking confirming that it will not sell semaglutide in India within two weeks.

The court also issued summons to Sun Pharma, seeking its response to Novo's plea. The matter has been adjourned to 21 Februar...